Last reviewed · How we verify

NCT06014580: MADONNA

Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil

Active, enrolled Last updated 7 March 2025
What this trial tests

trial testing Observational study in Endometrial Cancer in 276 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
27 November 2023
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorLatin American Cooperative Oncology Group
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment276
Start date27 November 2023
Primary completion31 December 2025
Estimated completion31 December 2025
Sites7 locations across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Latin American Cooperative Oncology Group

Who can join

18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An evaluation of the molecular and epidemiological aspects of endometrial cancer in Brazil is necessary to understand the high frequency of advanced disease. A better understanding of the current situation will generate essential data for the future development of national or international cooperative programs that aim to improve outcomes in these patients and generate additional knowledge for much-needed clinical trials in this population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Observational study

Trials testing the same drug.

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

Other Latin American Cooperative Oncology Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06014580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing